` NAYA (NAYA Biosciences Inc) vs S&P 500 Comparison - Alpha Spread

NAYA
vs
S&P 500

Over the past 12 months, NAYA has underperformed S&P 500, delivering a return of -83% compared to the S&P 500's 8% growth.

Stocks Performance
NAYA vs S&P 500

Loading

Performance Gap
NAYA vs S&P 500

Sign Up to see
Performance Gap
Sign In
Sign Up

Performance By Year
NAYA vs S&P 500

Loading
NAYA
S&P 500
Add Stock

Competitors Performance
NAYA Biosciences Inc vs Peers

NAYA Biosciences Inc
Glance View

Market Cap
18.7m USD
Industry
Health Care

INVO BioScience, Inc. is a fertility company. The company is headquartered in Sarasota, Florida and currently employs 25 full-time employees. The company went IPO on 2008-11-11. The Company’s initial pipeline includes two novel Flex-NK Bispecific Antibodies. NY-303: its GPC3-targeted FLEX-NK Bispecific Antibody for Hepatocellular Carcinoma (HCC). NY-338: its CD38-targeted FLEX-NK Bispecific Antibody for Multiple Myeloma (MM) & Autoimmune Diseases. Its lead GPC3-targeting FLEX-NK bispecific antibody is entering Phase I/II clinical trials and positioned as a monotherapy option to address the unmet needs of the of hepatocellular carcinoma (HCC) patients not responding to standard of care with checkpoint inhibitors. INVOcell is its novel, FDA-cleared and CE-marked intravaginal culture (IVC) device. The company offers a viable alternative to vitro fertilization (IVF) that uses the female body for fertilization and incubation, keeping women at the center of the reproductive process.

NAYA Intrinsic Value
HIDDEN
Show
Back to Top